Last update: July 1, 2015
Minimal risk for breastfeeding and infant.
Human-like monoclonal antibody (IgG1 immunoglobulin) produced by DNA recombinant technology. Action is by blockage of endothelial growth factor. Has been used for treatment of several types of cancer. Useful for treatment of eye macular degeneration secondary to choroidal neovascularization.
Because of a high molecular weight and a protein structure, excretion into breast milk and absorption by infant's gut are highly unlikely.
Intravitreal injection: because small doses used and low level observed in the plasma and because neither trace in breast milk nor side-effects in the infant have been reported, treatment is likely safe while breastfeeding.
It has advantage over Bevacizumab because it does not inhibit Vascular Endothelial Growth Factor (VEGF) that is present in the breast milk.
No harmful effects on infants from treated mothers have been reported.
We do not have alternatives for Ранибицумаб since it is relatively safe.
Suggestions made at e-lactancia are done by APILAM´s pediatricians and pharmacists, and are based on updated scientific publications.
It is not intended to replace the relationship you have with your doctor but to compound it.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
e-lactancia is a resource recommended by Academy of Breastfeeding Medicine from United States of America
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM